ONVO

Organovo Holdings, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website organovo.com
Employees(FY) 18
ISIN US68620A2033

Performance

-3.15%

-25.53%

-40.1%

-66.02%

-68.47%

YTD

-72.66%

Profile

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Advanced Technical Analysis

Technical Analysis of ONVO 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 3 indicating strong bearish pressure, while the Oscillators Score of 53 suggests a neutral stance. The Technical Score of 28 further reinforces the bearish outlook, indicating that caution is warranted in the current market environment.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ONVO

Stock Rank

Recent News & Updates

2024-11-19 19:05
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting(Globenewswire)
2024-11-12 19:06
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases(Globenewswire)
2024-11-08 03:15
Organovo: Fiscal Q2 Earnings Snapshot(Yahoo Finance)
2024-07-15 20:05
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis(Globenewswire)
2024-06-02 23:52
ONVO Stock Earnings: Organovo Holdings Beats EPS, Misses Revenue for Q4 2024(Investorplace)
2024-05-20 20:05
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease(Globenewswire)
2024-05-13 23:00
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)(Globenewswire)
2024-05-08 19:29
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday(Investorplace)
2024-05-08 08:00
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering(Globenewswire)
2024-04-14 20:13
Organovo's fatty liver disease drug meets main goal in mid-stage study(Yahoo Finance)
2024-04-14 20:05
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo(Globenewswire)
2024-03-28 08:32
Top 15 3D Printing Companies in the US(Insidermonkey)
2024-02-08 04:52
Organovo: Fiscal Q3 Earnings Snapshot(Yahoo Finance)
2024-01-24 19:05
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn's and Colitis Congress(Globenewswire)
2024-01-08 19:05
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress(Globenewswire)
2023-12-05 19:05
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results(Globenewswire)
2023-11-12 19:05
CORRECTION Organovo Highlights FXR314 Combination Therapy Potential and Plan(Globenewswire)
2023-11-09 16:08
Organovo: Fiscal Q2 Earnings Snapshot(Yahoo Finance)
2023-11-07 19:05
Organovo Highlights FXR314 Combination Therapy Potential and Plan(Globenewswire)
2023-10-09 19:18
ONVO: A Company With Great Technology to Impact Health Care(Yahoo Finance)
2023-09-08 00:46
Organovo to Participate in the H.C. Wainwright Global Investment Conference(Yahoo Finance)
2023-08-25 07:36
Is Organovo Holdings (ONVO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap(Yahoo Finance)
2023-08-22 20:05
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data(Yahoo Finance)
2023-07-11 15:01
Net Asset Value(s)(Yahoo Finance)
2023-05-24 22:49
Cathie Wood is Selling These 12 Stocks in 2023(Yahoo Finance)
2023-03-20 20:05
Organovo Announces FXR Program(Yahoo Finance)
2023-02-09 16:12
Will Organovo Holdings (NASDAQ:ONVO) Spend Its Cash Wisely?(Yahoo Finance)
2022-11-14 19:05
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohns Disease Drug Candidates(Yahoo Finance)
2022-09-05 20:20
Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference(Yahoo Finance)
2022-09-05 20:05
Organovo Announces Postponement of Annual Meeting of Stockholders(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.